High-Impact Cancer Research 2019

  • 21-26 October 2019
  • Harvard Medical School, Boston, MA, United States

High-Impact Cancer Research 2019 is a course dedicated to the wide spectrum of cancer science and the skills necessary to envision, design, and lead cutting-edge cancer research.

High-Impact Cancer Research 2019 covers topics such as:

  • Characteristic Biology of Tumors and Cancer Cells
    • Oncogenes and signal transduction
    • Cell proliferation and cell cycle control
    • P53 And Li-Fraumeni syndrome
    • Inherited predisposition
    • Programmed cell death
    • Epigenetics
    • Tumor microenvironment
    • Mitochondria and metabolism
    • Protein homeostasis and autophagy
    • Invasion and metastasis (EMT)
    • Non-coding RNAs and cancer
    • Tumor heterogeneity and clonal evolution
    • RNA expression profiles
    • Mutational signatures
  • The Cancer Problem
    • Introduction to clinical cancer problems
    • The worldwide cancer problem
    • Introduction to cancer epidemiology
    • Neoplasia and the pathology of cancer
    • The ten most important cancer research papers published in the past year
    • Introduction to cancer therapy
    • Hallmarks of cancer, a central paradigm of cancer biology
  • State-of-the-Art Approaches to Cancer Study
    • Zebrafish models of cancer
    • Animal models: from mouse to man
    • Human tumor models
    • Cell Llnes, NCI 60, CCLE, and newly derived lines
  • Prevention and Risk Identification
    • Environmental carcinogenesis
    • Epidemiology and cancer risk identification
    • Global tobacco epidemic
    • Diet, obesity, and cancer
    • HPV vaccine and how it works
    • Tobacco control strategies
    • Potential impact of the oncovirus vaccine across the globe
  • Immunotherapy
    • Immunogenomics: neoantigens to vaccines
    • Immunology as a basis to understand immunotherapy
    • Clinical trials for immunotherapy
    • Rational targeting of Hodgkin disease with immuno-oncology approaches
    • Immuno-oncology aspects and function of myeloid cells
    • Mouse models for immunotherapeutics
    • Discovery of novel targets for cancer immunotherapy
    • CAR-T Cells
    • Next-generation immunotherapy companies
    • T cell exhaustion
  • Therapy and Drug Development
    • Surgical therapy
    • Cytotoxics
    • Pharmacodynamics
    • Radiation therapy
    • Small molecule discovery and chemical biology
    • Pharmacokinetics
    • Government oversight
    • Clinical trials: IRB, Phase I, II, and III
    • From -Omics to target identification
    • Challenges and opportunities in development of molecularly-defined basket trials
    • Opportunities and challenges in developing first-in-class innovative agents
    • Drug discovery: nanotechnology, targeting, and RNA therapeutics
    • Antibody-based therapeutics in oncology
    • Development of biomarkers for precision cancer medicine
    • Therapeutic targeting of ubiquitin ligase activity
    • Innovation: new therapeutic strategies
    • Role of venture capital in the creation of new oncology therapeutics companies
    • Polymeric nanoparticles: tumor microenvironment variability and implications for new nanoparticle design and development
    • Case Studies:
  • Breast Cancer
    • Clinical predispositions to breast and ovarian cancer
    • Cellular and molecular heterogeneity in breast cancer
    • Breast cancer triple negative
    • Breast cancer screening
    • Hormone-responsive breast cancer
    • HER2-driven breast cancer
    • Disparities in breast cancer
    • Breast cancer metastasis and metastatic niches
  • Infection from Carcinogenic Organisms
    • Viral oncology: RNA viruses and oncogenes
    • Infectious causes of cancer overview
    • EBV: the first human cancer virus
    • Viral oncology: DNA viruses and tumor suppressor genes
    • Hepatocellular cancer: the role of viruses and inflammation
  • Lung Cancer
    • Genomic approaches in lung cancer
    • Introduction to lung cancer
    • Lung cancer: resistance to targeted therapies and impact on therapeutic strategies
    • Identifying and overcoming resistance to therapy in cancers
    • RAS, lung cancer, and the hunt for new therapeutic strategies
    • Combination therapies in lung cancer
  • Cervical Cancer
    • Cervical cancer: clinical perspectives
    • Cervical cancer: historical perspectives
    • Cervical cancer screening
  • Leukemia and Lymphoma
    • Hematological disorders
    • Hematological malignancies
    • Hematological stem cells
    • Transplantation therapies
    • The leukemic niche
    • Leukemia-initiating cells
    • Myeloid neoplasms (AML, MDS, Pmpns)
    • Targeted therapy: CML and Gleevec
    • CLL
    • Role of genetics and clonal evolution
    • Plasma cell neoplasms
    • B-cell lymphomas (including Hodgkin lymphoma)
  • Childhood Leukemia and Young Adult Solid Tumors
    • Young adult cancers
    • Childhood leukemia
  • Melanoma
    • DNA damage and repair
    • Melanoma
    • Immunotherapy in melanoma
    • BRAF therapy
  • Colon Cancer
    • Progression and tumor evolution
    • Clinical introduction to colon cancer
    • Screening for colon cancer

High-Impact Cancer Research 2019 brings together:

  • Clinical Researchers
  • Basic Researchers
  • Leaders of Cancer-Focused Organizations: Scientific, Policy, and Financial
  • Population Researchers
  • Top-­Flight Trainees

High-Impact Cancer Research 2019 will be held in Boston, MA, United States on 21-26 October 2019.


Harvard Medical School
25 Shattuck St.,
United States
  View all Hotels near Venue
11900-12900 US Dollar
Harvard Medical School
Rentalcars Savings

Past and Future Events

  • High-Impact Cancer Research 2019 - 21-26 Oct 2019, Boston, United States (75183)
  • High-Impact Cancer Research 2019 - 8-12 Apr 2019, Boston, United States (75182)
  • High-Impact Cancer Research 2018 - 2 Nov 2018, Boston, United States (75181)


Please, check the official conference website for possible changes, before you make any traveling arrangements

Prices are for evaluation only.

Other Events with Similar Categories